Prescription Drugs: FDA Has Met Most Performance Goals for Reviewing Applications

Home > Diane Publishing Books >

Our Price: $25.00

By Marcia G. Crosse (au)
Year: 2012
Pages: 52
Binding Paperback
ISBN 978-1-4578-3201-7

Product Code: 1457832011

Description

The FDA is responsible for overseeing the safety and efficacy of drugs and biologics sold in the U.S. New drugs and biologics must be reviewed by FDA before they can be marketed. The FDA reviews new drug applications (NDA), biologic license applications (BLA), and efficacy supplements that propose changes to the way approved drugs and biologics are marketed or used. This report: (1) examines trends in FDAäó»s NDA and BLA review performance for FY 2000 through 2010; (2) examines trends in FDAäó»s efficacy supplement review performance for FYs 2000 through 2010; and (3) describes issues that have been raised about the drug and biologic review processes and steps FDA is taking that address them. A print on demand report.

Share your knowledge of this product with other customers... Be the first to write a review